Target Name: MIR1825
NCBI ID: G100302183
Review Report on MIR1825 Target / Biomarker Content of Review Report on MIR1825 Target / Biomarker
MIR1825
Other Name(s): hsa-mir-1825 | microRNA 1825 | MIRN1825 | Hsa-mir-1825 | MicroRNA 1825 | hsa-miR-1825

MIR1825: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder that affects millions of people worldwide. The exact cause of MS is not known, but it is believed to involve an interplay of genetic, environmental, and immunological factors. MS patients experience a range of symptoms, including muscle weakness, fatigue, vision problems, and pain. The treatment options for MS are limited, and there is a significant need for new and effective drugs to manage the disease.

MIR1825 is a protein that is expressed in the central nervous system (CNS) of individuals with MS. It has been shown to be involved in the development and progression of MS, and it has potential as a drug target or biomarker. In this article, we will discuss the potential of MIR1825 as a drug target and biomarker for MS, and the current research that is being conducted to investigate its potential.

Potential Drug Target

MIR1825 is a protein that is expressed in the CNS of individuals with MS, and it has been shown to play a role in the development and progression of the disease. Several studies have shown that MIR1825 is involved in the regulation of immune cells in the CNS, and that it is potential target for drugs that can modulate the immune system.

One of the main ways that MIR1825 is thought to contribute to MS is by regulating the activity of T cells, a type of immune cell that is involved in the development and progression of the disease. T cells are known to play a key role in triggering the immune response in response to an infection, and they are believed to be involved in the destruction of the myelin sheath that is affected in MS.

MIR1825 has been shown to interact with the immune system in a number of ways, and it is thought to play a role in the regulation of T cell function. Several studies have shown that MIR1825 can modulate the activity of T cells in a variety of ways, including by regulating the production of T cells, the activation of T cells, and the proliferation of T cells.

In addition to its role in T cell regulation, MIR1825 is also thought to be involved in the regulation of inflammation in the CNS. Inflammation is a key feature of MS, and it is believed to contribute to the development and progression of the disease. MIR1825 has been shown to be involved in the regulation of inflammation in the CNS by regulating the production of pro-inflammatory cytokines.

Potential Biomarker

MIR1825 is also thought to be a potential biomarker for MS, as it has been shown to be involved in the development and progression of the disease. Several studies have shown that MIR1825 levels are elevated in individuals with MS, and that they can be used as a biomarker for the disease.

One of the main potential applications of MIR1825 as a biomarker for MS is its potential to serve as a target for drugs that can modulate the immune system and the regulation of inflammation in the CNS. Several studies have shown that MIR1825 is involved in the regulation of T cell function and that it is a potential target for drugs that can modulate the immune system.

In addition to its potential as a drug target, MIR1825 is also

Protein Name: MicroRNA 1825

The "MIR1825 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1825 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B